CNR1 and schizophrenia: Indeed, CB1r pharmacological blockade has shown therapeutic potential in animal models of schizophrenia developed by the antagonism of N-methyl-D-aspartate (NMDA) receptors (NMDAr) by phencyclidine (PCP) or MK-801 [318].